{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:49:34Z","timestamp":1790617774611,"version":"4.1.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110920"],"award-info":[{"award-number":["W81XWH2110920"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019329","name":"Emerson Collective","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1053\/j.semnuclmed.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T03:18:32Z","timestamp":1689650312000},"page":"663-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer"],"prefix":"10.1053","volume":"53","author":[{"given":"Suresh","family":"Alati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-7385","authenticated-orcid":false,"given":"Sangeeta Ray","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0001","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0002","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0003","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00259-022-06016-z","article-title":"Targeted \u03b1-therapy using astatine (211At)-labeled PSMA1, 5, and 6: A preclinical evaluation as a novel compound","volume":"50","author":"Watabe","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0004","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1432-1033.1990.tb19466.x","article-title":"Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors","volume":"194","author":"Christensson","year":"1990","journal-title":"Eur J Biochem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0006","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2967\/jnumed.120.243295","article-title":"Radionuclide therapy in prostate cancer: From standalone to combination PSMA theranostics","volume":"62","author":"Sandhu","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0007","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0008","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2967\/jnumed.121.263618","article-title":"mCRPC patients receiving 225Ac-PSMA-617 therapy in post androgen deprivation therapy setting: Response to treatment and survival analysis","volume":"63","author":"Sathekge","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0009","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2967\/jnumed.121.262098","article-title":"An improved 211At-labeled agent for PSMA-targeted \u03b1-therapy","volume":"63","author":"Mease","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0010","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","article-title":"(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-pentanedioic acid for PSMA-targeted alpha-particle radiopharmaceutical therapy","volume":"57","author":"Kiess","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0011","first-page":"6095","article-title":"An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer","volume":"60","author":"McDevitt","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0012","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.pcan.4500543","article-title":"In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen","volume":"5","author":"Li","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0013","first-page":"67","article-title":"213Bi-labeled prostate-specific membrane antigen-targeting agents induce DNA double-strand breaks in prostate cancer xenografts","volume":"32","author":"Nonnekens","year":"2017","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0014","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2967\/jnumed.120.256388","article-title":"Preclinical evaluation of (213)Bi-and (225)Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer","volume":"62","author":"Banerjee","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0015","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","article-title":"Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy?","volume":"46","author":"dos Santos","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0016","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.3390\/ijms22094815","article-title":"Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer","volume":"22","author":"Stenberg","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2967\/jnumed.119.229393","article-title":"Preclinical evaluation of 203\/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer","volume":"61","author":"Banerjee","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0018","doi-asserted-by":"crossref","first-page":"17800","DOI":"10.1038\/s41598-019-54150-w","article-title":"Alpha-PET for prostate cancer: Preclinical investigation using 149Tb-PSMA-617","volume":"9","author":"Umbricht","year":"2019","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0019","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2967\/jnumed.118.219592","article-title":"A single dose of 225Ac-RPS-074 induces a complete tumor response in an LNCaP xenograft model","volume":"60","author":"Kelly","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"177Lu-labeled albumin-binder\u2013conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0021","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00259-020-05150-w","article-title":"A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals","volume":"48","author":"Kalidindi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0022","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1078-0432.CCR-19-2268","article-title":"Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer","volume":"26","author":"Hammer","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0023","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1053\/j.semnuclmed.2023.02.002","article-title":"Preclinical imaging of prostate cancer","volume":"53","author":"Olkowski","year":"2023","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0024","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.semnuclmed.2019.02.003","article-title":"Radionuclide therapy of metastatic prostate cancer","volume":"49","author":"Kratochwil","year":"2019","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0025","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","article-title":"Current Status of prostate-specific membrane antigen targeting in nuclear medicine: Clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer","volume":"46","author":"Kratochwil","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0027","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.semnuclmed.2015.10.005","article-title":"Radioimmunotherapy for prostate cancer: Current status and future possibilities","volume":"46","author":"Evans-Axelsson","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0028","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.semnuclmed.2019.11.002","article-title":"Dosimetry, radiobiology and synthetic lethality: Radiopharmaceutical therapy (RPT) with alpha-particle-emitters","volume":"50","author":"Sgouros","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0029","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0030","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1021\/acs.molpharmaceut.1c00711","article-title":"Evaluation of 177Lu and 47Sc picaga-linked, prostate-specific membrane antigen-targeting constructs for their radiotherapeutic efficacy and dosimetry","volume":"18","author":"Vaughn","year":"2021","journal-title":"Mol Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0031","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0032","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s13139-023-00804-7","article-title":"161Tb-PSMA unleashed: A promising new player in the theranostics of prostate cancer","volume":"57","author":"Al-Ibraheem","year":"2023","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0033","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.7150\/thno.38882","article-title":"Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer","volume":"10","author":"Shen","year":"2020","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0034","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.115.155929","article-title":"Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen","volume":"56","author":"Kiess","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0035","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/1874471011104040306","article-title":"Actinium-225 in targeted alpha-particle therapeutic applications","volume":"4","author":"Scheinberg","year":"2011","journal-title":"Curr Radiopharm"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0036","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225actinium and 213bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0037","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijrobp.2014.12.061","article-title":"Radium-223 in the treatment of osteoblastic metastases: A critical clinical review","volume":"91","author":"Humm","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2022.1071086","article-title":"Targeted thorium-227 conjugates as treatment options in oncology","volume":"9","author":"Karlsson","year":"2023","journal-title":"Front Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0039","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0040","doi-asserted-by":"crossref","first-page":"eaag3326","DOI":"10.1126\/scisignal.aag3326","article-title":"PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer","volume":"10","author":"Caromile","year":"2017","journal-title":"Sci Signal"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0041","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jcb.10661","article-title":"Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer","volume":"91","author":"Ghosh","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0042","first-page":"5237","article-title":"In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen","volume":"60","author":"Smith-Jones","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0043","first-page":"610","article-title":"Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor","volume":"44","author":"Smith-Jones","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0044","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pros.10281","article-title":"Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice","volume":"58","author":"Vallabhajosula","year":"2004","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1046\/j.1525-1411.2001.003001001.x","article-title":"An \u03b1-particle emitting antibody ([213Bi] J591) for radioimmunotherapy of prostate cancer","volume":"3","author":"George","year":"2001","journal-title":"Prostate J"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0046","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","article-title":"Tumor therapy with targeted atomic nanogenerators","volume":"294","author":"McDevitt","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0047","article-title":"Preliminary studies using At-211-labeled anti-PSMA MAb for treatment of metastatic prostate cancer in a mouse model","volume":"50","author":"Wilbur","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0048","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/bc1005625","article-title":"Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in 211At- and 125I-labeled closo-decaborate(2-) conjugates of Fab\u2032 as a means of decreasing kidney retention","volume":"22","author":"Wilbur","year":"2011","journal-title":"Bioconjugate Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0049","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.1038\/s41598-020-66285-2","article-title":"Development of 177Lu-scFvD2B as a potential immunotheranostic agent for tumors overexpressing the prostate specific membrane antigen","volume":"10","author":"Carpanese","year":"2020","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0050","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","article-title":"Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy","volume":"48","author":"Ruigrok","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0051","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5015","article-title":"Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0052","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0053","doi-asserted-by":"crossref","unstructured":"LeBeau AM, Kostova M, Craik CS, et al. Prostate-specific antigen: An overlooked candidate for the targeted treatment and selective imaging of prostate cancer. 2010;391(4):333-343.","DOI":"10.1515\/bc.2010.044"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0054","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/s41467-018-04107-w","article-title":"Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer","volume":"9","author":"McDevitt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0055","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.7150\/thno.31179","article-title":"Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics","volume":"9","author":"Timmermand","year":"2019","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0056","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-20-3614","article-title":"PSA-targeted alpha-, beta-, and positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates","volume":"27","author":"Veach","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0057","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203820119","article-title":"Delta-like ligand 3\u2013targeted radioimmunotherapy for neuroendocrine prostate cancer","volume":"119","author":"Korsen","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0059","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","article-title":"Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0060","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1158\/1078-0432.CCR-21-3858","article-title":"CUB domain-containing protein 1 (CDCP1) is a target for radioligand therapy in castration-resistant prostate cancer, including PSMA null disease","volume":"28","author":"Zhao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0061","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: Structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0062","first-page":"241","article-title":"Prostate-specific membrane antigen as a target for cancer imaging and therapy. (1827-1936 (Electronic))","volume":"59","author":"Kiess","year":"2015","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0063","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1021\/jm800111u","article-title":"Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)","volume":"51","author":"Banerjee","year":"2008","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0064","doi-asserted-by":"crossref","first-page":"12711","DOI":"10.1021\/ja104591m","article-title":"A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules","volume":"132","author":"Zhang","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0065","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1021\/jm801055h","article-title":"Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer","volume":"51","author":"Chen","year":"2008","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0066","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2967\/jnumed.112.111203","article-title":"First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer","volume":"54","author":"Barrett","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0067","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","article-title":"Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer","volume":"69","author":"Hillier","year":"2009","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0068","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00259-017-3665-9","article-title":"Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0069","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm800994j","article-title":"A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer","volume":"52","author":"Maresca","year":"2009","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0070","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1021\/jm100623e","article-title":"68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer","volume":"53","author":"Banerjee","year":"2010","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0071","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2967\/jnumed.114.149062","article-title":"Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates","volume":"56","author":"Banerjee","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0072","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0073","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0074","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies","volume":"56","author":"Weineisen","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0075","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","article-title":"177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy","volume":"46","author":"Banerjee","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0076","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13550-020-00740-z","article-title":"Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: Influence of the stereoconfiguration on pharmacokinetics","volume":"10","author":"Wurzer","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0077","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2967\/jnumed.120.254516","article-title":"Comparative preclinical biodistribution, dosimetry, and endoradiotherapy in metastatic castration-resistant prostate cancer using 19F\/177lu-rhPSMA-7.3 and 177lu-PSMA I&T","volume":"62","author":"Yusufi","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0078","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2967\/jnumed.121.263371","article-title":"Synthesis and preclinical evaluation of 177lu-labeled radiohybrid PSMA ligands for endoradiotherapy of prostate cancer","volume":"63","author":"Wurzer","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0079","doi-asserted-by":"crossref","first-page":"14991","DOI":"10.1002\/anie.201908964","article-title":"A bivalent inhibitor of prostate specific membrane antigen radiolabeled with copper-64 with high tumor uptake and retention","volume":"58","author":"Zia","year":"2019","journal-title":"Angew Chem Int Ed"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2967\/jnumed.120.251579","article-title":"Therapeutic efficacy of a bivalent inhibitor of prostate-specific membrane antigen labeled with 67Cu","volume":"62","author":"McInnes","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0081","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1021\/acs.jmedchem.2c00852","article-title":"New PSMA-targeting ligands: Transformation from diagnosis (ga-68) to radionuclide therapy (Lu-177)","volume":"65","author":"Zha","year":"2022","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0082","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1039\/D0SC06867E","article-title":"Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand","volume":"12","author":"Abou","year":"2021","journal-title":"Chem Sci"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0083","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.3390\/ijms22115702","article-title":"Design and evaluation of 223Ra-labeled and anti-PSMA targeted NaA nanozeolites for prostate cancer therapy\u2014Part II. Toxicity, pharmacokinetics and biodistribution","volume":"22","author":"Lankoff","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0084","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11307-019-01404-8","article-title":"Preclinical dosimetry, imaging, andtargeted radionuclide therapy studies of Lu-177-labeled albumin-binding, PSMA-targeted CTT1403","volume":"22","author":"Ling","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0085","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0086","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acs.bioconjchem.8b00919","article-title":"Bench to bedside: Albumin binders for improved cancer radioligand therapies","volume":"30","author":"Lau","year":"2019","journal-title":"Bioconjugate Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0087","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00259-022-05837-2","article-title":"Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer","volume":"49","author":"Tschan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0088","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.7150\/thno.18719","article-title":"177Lu-labeled phosphoramidate-based PSMA inhibitors: The effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice","volume":"7","author":"Choy","year":"2017","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0089","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2967\/jnumed.122.264857","article-title":"A single-arm, low-dose, prospective study of 177Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"64","author":"Wang","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0090","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2967\/jnumed.120.242263","article-title":"177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer","volume":"61","author":"Zang","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0091","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2967\/jnumed.116.188722","article-title":"Dual-target binding ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer","volume":"58","author":"Kelly","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0092","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00259-018-4004-5","article-title":"Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors","volume":"45","author":"Kelly","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0093","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2967\/jnumed.118.221150","article-title":"Albumin-binding PSMA ligands: Implications for expanding the therapeutic window","volume":"60","author":"Kelly","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0094","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1021\/acs.molpharmaceut.0c00060","article-title":"Preclinical evaluation of a high-affinity sarcophagine-containing PSMA ligand for 64Cu\/67Cu-based theranostics in prostate cancer","volume":"17","author":"Kelly","year":"2020","journal-title":"Mol Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0095","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","article-title":"Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors","volume":"29","author":"Wang","year":"2018","journal-title":"Bioconjugate Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0096","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","article-title":"Albumin-binding PSMA ligands: Optimization of the tissue distribution profile","volume":"15","author":"Bene\u0161ov\u00e1","year":"2018","journal-title":"Mol Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0097","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical development of novel PSMA-targeting radioligands: Modulation of albumin-binding properties to improve prostate cancer therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0098","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1021\/acs.molpharmaceut.0c00199","article-title":"Combined application of albumin-binding [177Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: Optimization of the pharmacokinetics","volume":"17","author":"Borgna","year":"2020","journal-title":"Mol Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0099","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.1c00994","article-title":"Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy","volume":"19","author":"Borgna","year":"2022","journal-title":"Mol Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0100","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.3390\/cancers14225651","article-title":"[225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: Preclinical evaluation and comparison with [225Ac]Ac-PSMA-617","volume":"14","author":"Busslinger","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0101","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","article-title":"Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: Preclinical dosimetry and endoradiotherapy studies","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol Pharmaceutics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0102","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13550-022-00935-6","article-title":"Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225","volume":"12","author":"Meyer","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0103","doi-asserted-by":"crossref","first-page":"7203","DOI":"10.7150\/thno.78043","article-title":"Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin","volume":"12","author":"Reissig","year":"2022","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0104","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2967\/jnumed.122.264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: A real-world scenario management based long-term outcome study","volume":"64","author":"Ballal","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0105","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2967\/jnumed.121.261977","article-title":"Improved 223Ra therapy with combination epithelial sodium channel blockade","volume":"62","author":"Abou","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0106","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.euf.2021.06.006","article-title":"Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications","volume":"8","author":"Sheehan","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0107","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.3390\/biomedicines10123020","article-title":"Pharmacological optimization of PSMA-based radioligand therapy","volume":"10","author":"van der Gaag","year":"2022","journal-title":"Biomedicines"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0108","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0109","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1158\/1078-0432.CCR-21-0342","article-title":"Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate by a dual mode of action in prostate cancer models","volume":"27","author":"Hammer","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0110","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2967\/jnumed.121.262186","article-title":"Pretargeting: A path forward for radioimmunotherapy","volume":"63","author":"Cheal","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0111","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"L\u00fcckerath","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0112","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0114","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/cancers13020232","article-title":"Chemotherapy-induced upregulation of somatostatin receptor-2 increases the uptake and efficacy of 177Lu-DOTA-octreotate in neuroendocrine tumor cells","volume":"13","author":"Shah","year":"2021","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0116","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0117","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2020.06.020","article-title":"DNA repair and prostate cancer: A field ripe for harvest","volume":"78","author":"Bryce","year":"2020","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0118","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.3390\/ijms23148037","article-title":"Preclinical assessment of the combination of PSMA-targeting radionuclide therapy with PARP inhibitors for prostate cancer treatment","volume":"23","author":"Ruigrok","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0119","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0121","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrurol.2013.42","article-title":"Targeting GRPR in urological cancers\u2014from basic research to clinical application","volume":"10","author":"Mansi","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0122","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled bombesin analogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0123","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","article-title":"Prostate cancer theranostics targeting gastrin-releasing peptide receptors","volume":"20","author":"Baratto","year":"2018","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0124","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0125","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-10-1186","article-title":"Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)","volume":"71","author":"Wild","year":"2011","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0126","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/ijc.32401","article-title":"Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26","volume":"145","author":"Mitran","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0127","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-08-3145","article-title":"Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid\u2013conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides","volume":"15","author":"Mansi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0128","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2967\/jnumed.112.112169","article-title":"Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin","volume":"54","author":"Dumont","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: Preclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s41181-020-00115-8","article-title":"Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist","volume":"5","author":"Hofstetter","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0131","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1007\/s00259-022-05926-2","article-title":"Safety of [177Lu]Lu-NeoB treatment: A preclinical study characterizing absorbed dose and acute, early, and late organ toxicity","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0132","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/ph15060728","article-title":"Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer","volume":"15","author":"Huynh","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0133","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2967\/jnumed.120.257758","article-title":"A radiotracer for molecular imaging and therapy of gastrin-releasing peptide receptor\u2013positive prostate cancer","volume":"63","author":"Bratanovic","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0134","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7150\/thno.13580","article-title":"In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.06.007_bib0135","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2967\/jnumed.119.231282","article-title":"Development of improved tumor-residualizing, GRPR-targeted agents: Preclinical comparison of an endolysosomal trapping approach in agonistic and antagonistic constructs","volume":"61","author":"Zhang","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:56:23Z","timestamp":1782485783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299823000533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0001299823000533"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.06.007","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}